Forbius to Present at Two Upcoming Investor Conferences in November

  • Jefferies 2018 London Healthcare Conference &
  • Evercore ISI 2018 Healthcare Conference in Boston

(November 7, 2018) – Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, announced that Ilia Tikhomirov, CEO of Forbius, will be presenting at two upcoming investor conferences in November.


Details for the presentations:

Event: Jefferies 2018 London Healthcare Conference

Date: Wednesday, November 14, 2018

Time: 10:40 a.m. GMT


Event: Evercore ISI Healthcare Conference

Date: Wednesday, November 28, 2018

Time: 2:20 p.m. EST


About Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer

Forbius is a clinical stage protein engineering company that designs, develops, and commercializes biotherapeutics for the treatment of fibrosis and cancer. Our current focus is the development of agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.

Our lead program targeting the TGF-beta pathway is AVID200. AVID200 is a rationally designed and highly potent TGF-beta 1 & 3 inhibitor. This TGF-beta isoform selectivity was chosen in order to achieve an optimal therapeutic index. The AVID200 program has been cleared by the FDA for two Phase 1b clinical trials in fibrotic indications, as well as a Phase 1 clinical trial in solid tumors. Additional clinical trials in fibrotic indications are planned for 2019.

Forbius' lead program targeting the EGFR pathway is AVID100. AVID100 is an anti-EGFR antibody-drug conjugate. This program has completed a Phase 1 clinical trial and has commenced Phase 2a clinical trials in EGFR overexpressing solid tumors.



Claudia Resch